The Role of Therapeutic Anticoagulation in COVID-19

Coagulopathy has proven to be a common complication of the novel coronavirus SARS-CoV-2, with evidence of elevated D-dimers and fibrin degradation products associated with an increased incidence of thromboembolism. Despite emerging evidence describing the coagulopathy and its clinical relevance in C...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruth McGovern, Patrick Conway, Isabell Pekrul, Omar Tujjar
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Critical Care
Online Access:http://dx.doi.org/10.1155/2020/8835627
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546895591899136
author Ruth McGovern
Patrick Conway
Isabell Pekrul
Omar Tujjar
author_facet Ruth McGovern
Patrick Conway
Isabell Pekrul
Omar Tujjar
author_sort Ruth McGovern
collection DOAJ
description Coagulopathy has proven to be a common complication of the novel coronavirus SARS-CoV-2, with evidence of elevated D-dimers and fibrin degradation products associated with an increased incidence of thromboembolism. Despite emerging evidence describing the coagulopathy and its clinical relevance in COVID-19, fewer studies have addressed the potential role of empiric therapeutic anticoagulation in this setting. We report the case of a patient admitted to our intensive care unit (ICU) with severe acute respiratory distress syndrome (ARDS) secondary to COVID-19 whose clinical trajectory improved dramatically after initiation of a therapeutic dose of LMWH. The patient showed progressive elevation of fibrinogen and D-dimers despite a prophylactic dose of LMWH during her ICU stay. This was met with a moderate increase of troponin T-hs, an escalating need for vasopressors, and a progressive decrease in her P/F ratio despite preserved lung static compliance. Her platelet count was normal and had an elevated fibrinogen during the first week of ICU stay. The ECG was normal, and a bedside transthoracic echocardiogram showed no evidence of pulmonary embolism and a preserved EF with no regional wall motion abnormalities (RMWA). The chest X-ray was not dissimilar to previous exams, and the ABG showed hypoxia with normal pCO2 values. The decision was made to commence empiric therapeutic enoxaparin. The patient did not experience bleeding complications, and her clinical trajectory appeared to change dramatically. She was successfully extubated three days later and proceeded to clinical recovery and eventual discharge from the ICU. The available evidence shows that there is undoubtedly coagulopathy associated with COVID-19 with various subsequent forms of clinical manifestation described in the literature. Evidence also shows the benefits of heparin as an anticoagulant. From the discussion of this case report, however, it can be concluded that despite the plausible theoretical rationale, studies pertaining to the role of empiric therapeutic anticoagulation in this setting fall short of providing compelling evidence. Subsequently the role of empiric therapeutic anticoagulation in COVID-19 remains unclear with a pressing call for further research.
format Article
id doaj-art-a21d98cfeb324ed5a8db7da203c6d720
institution Kabale University
issn 2090-6420
2090-6439
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Critical Care
spelling doaj-art-a21d98cfeb324ed5a8db7da203c6d7202025-02-03T06:46:55ZengWileyCase Reports in Critical Care2090-64202090-64392020-01-01202010.1155/2020/88356278835627The Role of Therapeutic Anticoagulation in COVID-19Ruth McGovern0Patrick Conway1Isabell Pekrul2Omar Tujjar3Department of Anaesthesia, Intensive Care and Pain Medicine, Sligo University Hospital, Sligo, IrelandDepartment of Anaesthesia, Intensive Care and Pain Medicine, Sligo University Hospital, Sligo, IrelandDepartment of Anaesthesia, Ludwig-Maximilians-University of Munich, Munich, GermanyDepartment of Anaesthesia, Intensive Care and Pain Medicine, Sligo University Hospital, Sligo, IrelandCoagulopathy has proven to be a common complication of the novel coronavirus SARS-CoV-2, with evidence of elevated D-dimers and fibrin degradation products associated with an increased incidence of thromboembolism. Despite emerging evidence describing the coagulopathy and its clinical relevance in COVID-19, fewer studies have addressed the potential role of empiric therapeutic anticoagulation in this setting. We report the case of a patient admitted to our intensive care unit (ICU) with severe acute respiratory distress syndrome (ARDS) secondary to COVID-19 whose clinical trajectory improved dramatically after initiation of a therapeutic dose of LMWH. The patient showed progressive elevation of fibrinogen and D-dimers despite a prophylactic dose of LMWH during her ICU stay. This was met with a moderate increase of troponin T-hs, an escalating need for vasopressors, and a progressive decrease in her P/F ratio despite preserved lung static compliance. Her platelet count was normal and had an elevated fibrinogen during the first week of ICU stay. The ECG was normal, and a bedside transthoracic echocardiogram showed no evidence of pulmonary embolism and a preserved EF with no regional wall motion abnormalities (RMWA). The chest X-ray was not dissimilar to previous exams, and the ABG showed hypoxia with normal pCO2 values. The decision was made to commence empiric therapeutic enoxaparin. The patient did not experience bleeding complications, and her clinical trajectory appeared to change dramatically. She was successfully extubated three days later and proceeded to clinical recovery and eventual discharge from the ICU. The available evidence shows that there is undoubtedly coagulopathy associated with COVID-19 with various subsequent forms of clinical manifestation described in the literature. Evidence also shows the benefits of heparin as an anticoagulant. From the discussion of this case report, however, it can be concluded that despite the plausible theoretical rationale, studies pertaining to the role of empiric therapeutic anticoagulation in this setting fall short of providing compelling evidence. Subsequently the role of empiric therapeutic anticoagulation in COVID-19 remains unclear with a pressing call for further research.http://dx.doi.org/10.1155/2020/8835627
spellingShingle Ruth McGovern
Patrick Conway
Isabell Pekrul
Omar Tujjar
The Role of Therapeutic Anticoagulation in COVID-19
Case Reports in Critical Care
title The Role of Therapeutic Anticoagulation in COVID-19
title_full The Role of Therapeutic Anticoagulation in COVID-19
title_fullStr The Role of Therapeutic Anticoagulation in COVID-19
title_full_unstemmed The Role of Therapeutic Anticoagulation in COVID-19
title_short The Role of Therapeutic Anticoagulation in COVID-19
title_sort role of therapeutic anticoagulation in covid 19
url http://dx.doi.org/10.1155/2020/8835627
work_keys_str_mv AT ruthmcgovern theroleoftherapeuticanticoagulationincovid19
AT patrickconway theroleoftherapeuticanticoagulationincovid19
AT isabellpekrul theroleoftherapeuticanticoagulationincovid19
AT omartujjar theroleoftherapeuticanticoagulationincovid19
AT ruthmcgovern roleoftherapeuticanticoagulationincovid19
AT patrickconway roleoftherapeuticanticoagulationincovid19
AT isabellpekrul roleoftherapeuticanticoagulationincovid19
AT omartujjar roleoftherapeuticanticoagulationincovid19